LUSPATERCEPT INITIATED AT THE MAXIMUM-APPROVED DOSE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES WHO REQUIRE TRANSFUSIONS: PRIMARY ANALYSIS FROM MAXILUS (SIE 2026) - Oct 6, 2026 - Abstract #B07; Pres time: Sep 22, 2026; 10:25 AM - 11:40 AM; Location: PLENARY HALL; P3 | "Tx was well tolerated; few pts progressed to HR-MDS, in line with known rates, and none to AML. This primary analysis reinforces the favorable efficacy and safety profile of LUSPA at the maximum-approved dose in LR MDS."
Clinical • Hematological Malignancies • Myelodysplastic Syndrome
|
|
M. Della Porta1; M. D. Campelo2; V. Santini3; R. Buckstein4; L. Adès5; B. Bhatnagar6; L. Sahagun7; Y Lai7; D. Miteva8; A. Mcbride7; K. Madry9; L. Fletcher10; D. Deeren11; T. Cluzeau12; D. Valcárcel13; J. M. Torregrosa-Diaz14; S. Grosicki15; E. Von Der Heyde16; U. Platzbecker17; S. Venugopal18; A. M. Zeidan19
|